We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Agenus Inc | NASDAQ:AGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.39 | -3.52% | 10.70 | 10.70 | 11.24 | 11.425 | 10.61 | 11.01 | 399,122 | 21:50:40 |
LEXINGTON, Mass., July 29, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020. Agenus executives and thought leaders will host a video conference call and webcast at 8:30 a.m. ET.
Topics to be discussed:
Live Call: Dial 1-844-492-3727 (U.S.) or 1-412-317-5118 (International)
Webcast: The call will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or via https://www.webcaster4.com/Webcast/Page/1556/35715. A replay will be available approximately two hours after the call and will remain available until November 7, 2020.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio.
Contact
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-rd-update--second-quarter-earnings-report-301102427.html
SOURCE Agenus Inc.
Copyright 2020 PR Newswire
1 Year Agenus Chart |
1 Month Agenus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions